Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings Inc.

NEW YORK, April 17, 2026 — Baird Equity Research titled its February 9, 2026 report “Expect Shares Under Pressure Tomorrow.” Truist cut its price t...

MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Analysts Allegedly Misled by Guidance: Levi & Korsinsky

RBC Capital analyst Ryan Halsted maintained a Buy rating on Medpace Holdings yesterday and set a price target of $522.00. According to TipRanks, Ha...

RBC Capital Remains a Buy on Medpace Holdings (MEDP)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Medpace Holdings (MEDP) and Legend Biotech (LEGN)....

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MEDP	$520.60	+0.96%	629.90K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MEDP	$520.60	+1.0%	629.90K
3
4
5
6

MEDP

MEDP

Get Medpace Holdings Inc. Data in Excel

Get Medpace Holdings Inc. Data in Excel